Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 16/20 | 0.48 |
| ▸ | JAK2 | O60674 | 14/20 | 0.48 |
| ▸ | TYK2 | P29597 | 4/20 | 0.48 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
| ▸ | STK10 | O94804 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.48 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.48 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20918455 | 0.93 | JAK1 (0.56) | JAK1JAK2TYK2JAK3STK10 | |
| SCHEMBL20930854 | 0.86 | JAK1 (0.45) | JAK1JAK2TYK2JAK3STK10 | |
| SCHEMBL20918792 | 0.75 | JAK1 (0.55) | JAK1JAK2JAK3 | |
| SCHEMBL30356243 | 0.75 | JAK1 (0.55) | JAK1JAK2JAK3 | |
| SCHEMBL30356056 | 0.74 | JAK1 (0.71) | JAK1ABL1 | |
| SCHEMBL20930670 | 0.74 | JAK1 (0.51) | JAK1MERTK | |
| SCHEMBL20918015 | 0.74 | JAK1 (0.71) | JAK1ABL1 | |
| SCHEMBL20918456 | 0.73 | JAK1 (0.41) | JAK1ABL1 | |
| SCHEMBL20919114 | 0.73 | JAK2 (0.46) | JAK1JAK2JAK3AAK1BMP2K | |
| SCHEMBL30356176 | 0.73 | JAK2 (0.46) | JAK1JAK2JAK3AAK1BMP2K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | HK INNO.N CORPORATION (KR) | 2021-06-10 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | HK INNO.N CORPORATION (KR) | 2021-06-10 | — | — | US | disclosed |
| EP-3697787-A1 | HETEROCYCLIC COMPOUND AS A PROTEIN KINASE INHIBITOR | HK inno.N Corporation (KR) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019078619-A1 | HETEROCYCLIC COMPOUND AS A PROTEIN KINASE INHIBITOR | CJ HEALTHCARE CORPORATION (KR) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885JAK2 61/4885TYK2 174/4885 |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885JAK2 61/4885TYK2 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.